AR120246A1 - Aminas heteroaril-bifenilas para el tratamiento de las enfermedades por pd-l1 - Google Patents
Aminas heteroaril-bifenilas para el tratamiento de las enfermedades por pd-l1Info
- Publication number
- AR120246A1 AR120246A1 ARP200102872A ARP200102872A AR120246A1 AR 120246 A1 AR120246 A1 AR 120246A1 AR P200102872 A ARP200102872 A AR P200102872A AR P200102872 A ARP200102872 A AR P200102872A AR 120246 A1 AR120246 A1 AR 120246A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- independently selected
- alkylene
- haloalkyl
- Prior art date
Links
- 102000008096 B7-H1 Antigen Human genes 0.000 title 1
- 108010074708 B7-H1 Antigen Proteins 0.000 title 1
- 239000004305 biphenyl Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229910003827 NRaRb Inorganic materials 0.000 abstract 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 4
- 229910018828 PO3H2 Inorganic materials 0.000 abstract 4
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 3
- 229910006069 SO3H Inorganic materials 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 abstract 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 abstract 2
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 abstract 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 1
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 abstract 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 1
- -1 CO2-C1−8 alkyl Inorganic materials 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000005113 hydroxyalkoxy group Chemical group 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962915771P | 2019-10-16 | 2019-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR120246A1 true AR120246A1 (es) | 2022-02-09 |
Family
ID=75538872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200102872A AR120246A1 (es) | 2019-10-16 | 2020-10-16 | Aminas heteroaril-bifenilas para el tratamiento de las enfermedades por pd-l1 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11866429B2 (https=) |
| EP (1) | EP4045037B1 (https=) |
| JP (1) | JP7686634B2 (https=) |
| KR (1) | KR20220083775A (https=) |
| CN (1) | CN114555080B (https=) |
| AR (1) | AR120246A1 (https=) |
| AU (1) | AU2020368392B2 (https=) |
| BR (1) | BR112022006279A2 (https=) |
| CA (1) | CA3152714A1 (https=) |
| CL (2) | CL2022000955A1 (https=) |
| CO (1) | CO2022004698A2 (https=) |
| CR (1) | CR20220216A (https=) |
| EC (1) | ECSP22038509A (https=) |
| IL (1) | IL291735A (https=) |
| MX (1) | MX2022004450A (https=) |
| PE (1) | PE20221764A1 (https=) |
| PH (1) | PH12022550877A1 (https=) |
| TW (1) | TWI873207B (https=) |
| WO (1) | WO2021076688A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7387616B2 (ja) | 2018-02-22 | 2023-11-28 | ケモセントリックス，インコーポレイティド | Ｐｄ－ｌ１アンタゴニストとしてのインダン－アミン |
| AU2020276277B2 (en) | 2019-05-15 | 2025-03-20 | Chemocentryx, Inc. | Triaryl compounds for treatment of PD-L1 diseases |
| BR112021025888A2 (pt) | 2019-07-10 | 2022-04-26 | Chemocentryx Inc | Indanos como inibidores de pd-l1 |
| CN114555080B (zh) | 2019-10-16 | 2025-10-10 | 凯莫森特里克斯股份有限公司 | 用于治疗pd-l1疾病的杂芳基联苯胺 |
| AU2020368393B2 (en) | 2019-10-16 | 2026-01-08 | Chemocentryx, Inc. | Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases |
| CN116322350A (zh) | 2020-09-25 | 2023-06-23 | 好侍健康食品株式会社 | 含有乳酸菌与脂肪酸的饲料及组合物 |
| CN115232109A (zh) * | 2021-04-25 | 2022-10-25 | 广东东阳光药业有限公司 | Pd-1/pd-l1类小分子抑制剂及其在药物中的应用 |
| CN113135895A (zh) * | 2021-04-30 | 2021-07-20 | 中国药科大学 | 一种新型联苯类衍生物及其制备方法与医药用途 |
| CN115010658B (zh) * | 2022-05-11 | 2023-06-27 | 南方医科大学 | 一种化合物及其制备方法与应用 |
| WO2024134466A1 (en) * | 2022-12-21 | 2024-06-27 | Arbutus Biopharma Corporation | Substituted arylamine compounds, substituted heteroarylamine compounds, and methods using same |
| WO2025171031A1 (en) * | 2024-02-07 | 2025-08-14 | Aligos Therapeutics, Inc. | Pd-l1 compounds with a bicyclic group |
| WO2025171025A1 (en) * | 2024-02-07 | 2025-08-14 | Aligos Therapeutics, Inc. | Pd-l1 compounds with a bicyclic group |
Family Cites Families (135)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1268002A (en) | 1917-09-12 | 1918-05-28 | William M Goodwin | Measuring instrument. |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| GB9604926D0 (en) | 1996-03-08 | 1996-05-08 | Sandoz Ltd | Organic compounds |
| DK1531822T3 (da) | 2002-06-12 | 2009-12-07 | Chemocentryx Inc | 1-aryl-4-substituerede piperazin derivater til anvendelse som CCR1 antagonister til behandlingen af inflammation og immunforstyrrelser |
| US7227035B2 (en) | 2002-11-18 | 2007-06-05 | Chemocentryx | Bis-aryl sulfonamides |
| US7420055B2 (en) | 2002-11-18 | 2008-09-02 | Chemocentryx, Inc. | Aryl sulfonamides |
| US6939885B2 (en) | 2002-11-18 | 2005-09-06 | Chemocentryx | Aryl sulfonamides |
| EP1748989A2 (en) | 2004-05-12 | 2007-02-07 | ChemoCentryx Inc | Aryl sulfonamides |
| ES2440965T3 (es) | 2005-01-14 | 2014-01-31 | Chemocentryx, Inc. | Heteroaril-sulfonamidas y CCR2 |
| US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| BRPI0612112A8 (pt) | 2005-06-22 | 2017-12-26 | Chemocentryx Inc | composto, composição farmacêutica, e, método de tratar doenças ou condições mediadas por ccr1. |
| US7790726B2 (en) | 2005-08-16 | 2010-09-07 | Chemocentryx, Inc. | Monocyclic and bicyclic compounds and methods of use |
| WO2007073432A2 (en) | 2005-10-11 | 2007-06-28 | Chemocentryx, Inc. | Piperidine derivatives and methods of use |
| DE602006018057D1 (de) | 2005-11-10 | 2010-12-16 | Chemocentryx Inc | Substituierte chinolone und verwendungsverfahren |
| US7671069B2 (en) | 2006-03-30 | 2010-03-02 | Chemocentryx, Inc. | Tricyclic, heteroaromatic compounds modulating CXCR4 and/ or CXCR7 |
| US7807704B2 (en) | 2006-03-30 | 2010-10-05 | Chemocentryx, Inc. | Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 |
| EP2402320A1 (en) | 2006-03-31 | 2012-01-04 | Novartis AG | Anorectic agents |
| WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
| US20100234364A1 (en) | 2006-07-14 | 2010-09-16 | Arindrajit Basak | Ccr2 inhibitors and methods of use thereof |
| MX2009000395A (es) | 2006-07-14 | 2009-01-29 | Chemocentryx Inc | Triazolil fenil bencenosulfonamidas. |
| US7683176B2 (en) | 2006-07-14 | 2010-03-23 | Chemocentryx, Inc. | Triazolyl pyridyl benzenesulfonamides |
| DK2155712T3 (en) | 2007-05-22 | 2016-12-19 | Chemocentryx Inc | 3- (imidazolyl) pyrazolo [3,4-b] pyridines |
| US7776877B2 (en) | 2007-06-22 | 2010-08-17 | Chemocentryx, Inc. | N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides |
| PL2175859T3 (pl) | 2007-07-12 | 2012-09-28 | Chemocentryx Inc | Skondensowane heteroarylopirydylo- i fenylo-benzenosulfonamidy jako modulatory CCR2 do leczenia zapalenia |
| JP5654467B2 (ja) | 2008-09-11 | 2015-01-14 | ケモセントリックス，インコーポレイティド | ４−アミノ−３−（イミダゾリル）−ピラゾロ［３，４−ｄ］ピリミジン |
| EP2352501B1 (en) | 2008-11-03 | 2014-01-01 | ChemoCentryx, Inc. | Compounds for use in the treatment of osteoporosis |
| MX2011004490A (es) | 2008-11-04 | 2011-07-20 | Chemocentryx Inc | Moduladores de cxcr7. |
| CA2965223C (en) | 2008-12-22 | 2019-09-24 | Chemocentryx, Inc. | C5ar antagonists |
| EP2480531B1 (en) | 2009-09-21 | 2014-11-05 | ChemoCentryx, Inc. | Pyrrolidinone carboxamide derivatives as chemerin-r (chemr23) modulators |
| WO2011082400A2 (en) | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
| PT2585064T (pt) | 2010-06-24 | 2017-08-08 | Chemocentryx Inc | Antagonistas do c5ar |
| EP2780338B1 (en) | 2011-11-14 | 2016-11-09 | Ignyta, Inc. | Uracil derivatives as axl and c-met kinase inhibitors |
| DK2785710T3 (en) | 2011-12-01 | 2017-12-04 | Chemocentryx Inc | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR (4) - ANTAGONISTS |
| MX356163B (es) | 2011-12-01 | 2018-05-16 | Chemocentryx Inc | Anilinas sustituidas como antagonistas de ccr(4). |
| EP2788000B1 (en) | 2011-12-06 | 2018-05-30 | Merck Sharp & Dohme Corp. | Pyrrolopyrimidines as janus kinase inhibitors |
| WO2013130811A1 (en) * | 2012-02-29 | 2013-09-06 | Chemocentryx, Inc. | Pyrazol-1-yl benzene sulfonamides as ccr9 antagonists |
| JP6272897B2 (ja) | 2012-11-29 | 2018-01-31 | ケモセントリックス，インコーポレイティド | Ｃｘｃｒ７アンタゴニスト |
| AU2013355054B2 (en) | 2012-12-07 | 2017-08-24 | Chemocentryx, Inc. | Diazole lactams |
| US9169248B2 (en) | 2012-12-21 | 2015-10-27 | Chemocentryx, Inc. | Diazole amides |
| JP6417419B2 (ja) | 2013-09-04 | 2018-11-07 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 免疫調節剤として有用な化合物 |
| SI3041828T1 (sl) | 2013-09-06 | 2018-10-30 | Aurigene Discovery Technologies Limited | 1,3,4-oksadiazolni in 1,3,4-tiadiazolni derivati kot imunomodulatorji |
| HRP20181052T1 (hr) | 2013-09-06 | 2018-09-07 | Aurigene Discovery Technologies Limited | Derivati 1,2,4-oksadiazola kao imunomodulatori |
| EP3076968B1 (en) | 2013-12-02 | 2019-04-17 | ChemoCentryx, Inc. | Ccr6 compounds |
| US9850225B2 (en) | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| JP6767096B2 (ja) | 2014-12-11 | 2020-10-14 | リティックス バイオファーマ エイエス | 免疫チェックポイント阻害剤の組み合わせ |
| MX2017013563A (es) | 2015-04-21 | 2018-07-06 | Gtx Inc | LIGANDOS DEGRADADORES SELECTIVOS DEL RECEPTOR ANDROGíNICO (SARD) Y SUS MíTODOS DE USO. |
| WO2016180537A1 (en) | 2015-05-13 | 2016-11-17 | Selvita S.A. | Substituted quinoxaline derivatives |
| ES2904252T3 (es) | 2015-05-21 | 2022-04-04 | Chemocentryx Inc | Moduladores de CCR2 |
| NL1041468B1 (en) | 2015-09-08 | 2017-03-22 | Bosch Gmbh Robert | Metal ring component of a drive belt for a continuously variable transmisson. |
| EP3156405A1 (en) * | 2015-10-13 | 2017-04-19 | Boehringer Ingelheim International GmbH | Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide |
| US10745382B2 (en) | 2015-10-15 | 2020-08-18 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| EP3365340B1 (en) | 2015-10-19 | 2022-08-10 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| TWI734715B (zh) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
| TWI724056B (zh) | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Ｃｘｃｒ２抑制劑 |
| US20170145025A1 (en) | 2015-11-19 | 2017-05-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| ES2916874T3 (es) | 2015-12-17 | 2022-07-06 | Incyte Corp | Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1 |
| AU2016379372A1 (en) | 2015-12-22 | 2018-08-02 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| EP3190103A1 (en) | 2016-01-08 | 2017-07-12 | Rijksuniversiteit Groningen | Inhibitors of the pd-1/pd-l1 protein/protein interaction |
| RU2743747C2 (ru) | 2016-01-20 | 2021-02-25 | Кемосентрикс, Инк. | 2-оксиндольные соединения |
| AU2017246228B2 (en) | 2016-04-04 | 2021-04-15 | Chemocentryx, Inc. | Soluble C5aR antagonists |
| ES2906460T3 (es) | 2016-05-06 | 2022-04-18 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| JP7075928B2 (ja) | 2016-05-23 | 2022-05-26 | 中国医学科学院薬物研究所 | フェニレート誘導体、調製及び医薬組成物及び使用 |
| ES2905980T3 (es) | 2016-05-26 | 2022-04-12 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| BR112018076534A2 (pt) | 2016-06-20 | 2019-04-02 | Incyte Corporation | compostos heterocíclicos como imunomoduladores |
| WO2018005374A1 (en) | 2016-06-27 | 2018-01-04 | Chemocentryx, Inc. | Immunomodulator compounds |
| US11078192B2 (en) | 2016-07-05 | 2021-08-03 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. | Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof |
| CN109689640B (zh) | 2016-07-08 | 2022-01-04 | 百时美施贵宝公司 | 可用作免疫调节剂的化合物 |
| MA45669A (fr) | 2016-07-14 | 2019-05-22 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| ES2941716T3 (es) | 2016-08-29 | 2023-05-25 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| US10144706B2 (en) | 2016-09-01 | 2018-12-04 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| WO2018045142A1 (en) | 2016-09-02 | 2018-03-08 | Polaris Pharmaceuticals, Inc. | Immune checkpoint inhibitors, compositions and methods thereof |
| JP7106572B2 (ja) | 2016-12-20 | 2022-07-26 | ブリストル－マイヤーズ スクイブ カンパニー | 免疫調節剤として有用な化合物 |
| WO2018119263A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds derivatives as pd-l1 internalization inducers |
| ES2874756T3 (es) | 2016-12-22 | 2021-11-05 | Incyte Corp | Derivados de triazolo[1,5-A]piridina como inmunomoduladores |
| WO2018119286A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| ES2899402T3 (es) * | 2016-12-22 | 2022-03-11 | Incyte Corp | Derivados de piridina como inmunomoduladores |
| EP3558990B1 (en) | 2016-12-22 | 2022-08-10 | Incyte Corporation | Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers |
| AU2017382870B2 (en) | 2016-12-22 | 2022-03-24 | Incyte Corporation | Benzooxazole derivatives as immunomodulators |
| CN106674136B (zh) | 2016-12-23 | 2019-07-02 | 中国医科大学 | 嘧啶类抗肿瘤化合物及其制备方法 |
| EP3564237A4 (en) | 2016-12-29 | 2020-06-10 | Shenzhen Chipscreen Biosciences Co., Ltd. | UREA COMPOUND AND PRODUCTION METHOD AND USE THEREOF |
| CN108395443B (zh) | 2017-02-04 | 2021-05-04 | 广州丹康医药生物有限公司 | 抑制程序性死亡受体配体1的环状化合物及其用途 |
| KR20190133714A (ko) | 2017-03-27 | 2019-12-03 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조정제로서 유용한 치환된 이소퀴놀린 유도체 |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| TW201841896A (zh) | 2017-04-26 | 2018-12-01 | 大陸商南京聖和藥業股份有限公司 | 作為pd—l1抑制劑的雜環類化合物 |
| CN108863963B (zh) | 2017-05-08 | 2022-05-27 | 南京圣和药物研发有限公司 | 作为pd-l1抑制剂的杂环类化合物 |
| WO2018222601A1 (en) | 2017-05-31 | 2018-12-06 | Chemocentryx, Inc. | 5-5 FUSED RINGS AS C5a INHIBITORS |
| CN110997674B (zh) | 2017-05-31 | 2022-12-20 | 凯莫森特里克斯股份有限公司 | 作为C5a抑制剂的6-5稠合环类 |
| AU2018306619B2 (en) | 2017-07-28 | 2022-06-02 | Chemocentryx, Inc. | Immunomodulator compounds |
| CN111225665B (zh) | 2017-08-08 | 2023-12-08 | 凯莫森特里克斯股份有限公司 | 大环免疫调节剂 |
| WO2019034172A1 (zh) | 2017-08-18 | 2019-02-21 | 上海轶诺药业有限公司 | 一种具有pd-l1抑制活性的化合物、其制备方法及用途 |
| CN118267479A (zh) | 2017-09-25 | 2024-07-02 | 凯莫森特里克斯股份有限公司 | 使用趋化因子受体2(ccr2)拮抗剂和pd-1/pd-l1抑制剂的联合治疗 |
| US20190275015A1 (en) | 2017-09-25 | 2019-09-12 | Chemocentryx, Inc. | Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor |
| US11492375B2 (en) | 2017-10-03 | 2022-11-08 | Bristol-Myers Squibb Company | Cyclic peptide immunomodulators |
| CN109665968B (zh) | 2017-10-16 | 2022-02-22 | 四川科伦博泰生物医药股份有限公司 | 并环化合物及其制备方法和用途 |
| CN109678796B (zh) | 2017-10-19 | 2023-01-10 | 上海长森药业有限公司 | Pd-1/pd-l1小分子抑制剂及其制备方法和用途 |
| CN109721527B (zh) | 2017-10-27 | 2024-03-12 | 广州丹康医药生物有限公司 | 一种新型抗pd-l1化合物、其应用及含其的组合物 |
| KR20200085836A (ko) | 2017-11-06 | 2020-07-15 | 주빌런트 프로델 엘엘씨 | Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체 |
| WO2019120297A1 (zh) | 2017-12-22 | 2019-06-27 | 上海海雁医药科技有限公司 | 免疫调节剂及其制法与医药上的用途 |
| KR102666727B1 (ko) | 2017-12-29 | 2024-05-21 | 광저우 맥시노벨 파마수티컬스 씨오., 엘티디. | 방향족 비닐 또는 방향족 에틸계 유도체, 그의 제조방법, 중간체, 약물조성물 및 용도 |
| JP7214752B2 (ja) | 2018-01-23 | 2023-01-30 | ブリストル－マイヤーズ スクイブ カンパニー | 免疫調節剤として有用な２，８－ジアシル－２，８－ジアザスピロ［５．５］ウンデカン化合物 |
| CA3088927C (en) | 2018-02-05 | 2023-03-21 | Abbisko Therapeutics Co., Ltd. | Biaryl derivative, preparation method therefor and pharmaceutical use thereof |
| TWI707849B (zh) | 2018-02-13 | 2020-10-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| JP7387616B2 (ja) | 2018-02-22 | 2023-11-28 | ケモセントリックス，インコーポレイティド | Ｐｄ－ｌ１アンタゴニストとしてのインダン－アミン |
| EP3759093B1 (en) | 2018-03-01 | 2022-11-30 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| SG11202008950PA (en) | 2018-03-13 | 2020-10-29 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation |
| WO2019174533A1 (zh) | 2018-03-13 | 2019-09-19 | 广东东阳光药业有限公司 | Pd-1/pd-l1类小分子抑制剂及其在药物中的应用 |
| CR20200520A (es) * | 2018-03-30 | 2021-03-09 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| WO2019192506A1 (en) | 2018-04-03 | 2019-10-10 | Betta Pharmaceuticals Co., Ltd | Immunomodulators, compositions and methods thereof |
| KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| WO2019217821A1 (en) | 2018-05-11 | 2019-11-14 | Incyte Corporation | Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators |
| WO2020011209A1 (zh) | 2018-07-11 | 2020-01-16 | 上海和誉生物医药科技有限公司 | 免疫抑制剂及其制备方法和在药学上的应用 |
| WO2020011243A1 (en) | 2018-07-12 | 2020-01-16 | Betta Pharmaceuticals Co., Ltd | Immunomodulators, compositions and methods thereof |
| EP3820572B1 (en) | 2018-07-13 | 2023-08-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US20210269440A1 (en) | 2018-07-19 | 2021-09-02 | Betta Pharmaceuticals Co., Ltd | Immunomodulators, compositions and methods thereof |
| US20210300909A1 (en) | 2018-07-19 | 2021-09-30 | Betta Pharmaceuticals Co., Ltd | Immunomodulators, compositions and methods thereof |
| US20210347785A1 (en) * | 2018-08-01 | 2021-11-11 | Shanghai Ennovabio Pharmaceuticals Co., Ltd. | Preparation and application of aromatic compound having immunoregulatory function |
| US20210236476A1 (en) | 2018-08-29 | 2021-08-05 | Chemocentryx, Inc. | Methods of treating cancer with small molecule pd-l1 inhibitors |
| CN109336857A (zh) | 2018-11-13 | 2019-02-15 | 南方医科大学 | 一种含取代联苯的黄酮及其应用 |
| CN109438263A (zh) | 2018-11-28 | 2019-03-08 | 南方医科大学 | 一种含取代联苯的萘及其应用 |
| CN109503546A (zh) | 2019-01-10 | 2019-03-22 | 南方医科大学 | 一种间苯二酚二苯甲醚及其应用 |
| EP3917927A4 (en) * | 2019-01-31 | 2022-10-26 | Betta Pharmaceuticals Co., Ltd | IMMUNE MODULATORS, COMPOSITIONS AND METHODS THEREOF |
| CN109776377B (zh) | 2019-02-01 | 2021-08-24 | 沈阳药科大学 | 吲哚啉类化合物及其制备方法和应用 |
| US20200297708A1 (en) | 2019-03-19 | 2020-09-24 | Chemocentryx, Inc. | Combination Therapy Using a Chemokine Receptor 2 (CCR2) Antagonist and a PD-1 and/or PD-L1 Inhibitor |
| CN109776445B (zh) | 2019-03-28 | 2022-12-06 | 中国药科大学 | 苯并噁二唑类化合物及其制备方法和医药用途 |
| AU2020276277B2 (en) | 2019-05-15 | 2025-03-20 | Chemocentryx, Inc. | Triaryl compounds for treatment of PD-L1 diseases |
| CN110200959A (zh) | 2019-05-30 | 2019-09-06 | 天津科技大学 | 一种黄酮类化合物的应用 |
| CN110128415B (zh) | 2019-05-31 | 2022-03-25 | 沈阳药科大学 | 用作免疫调节剂的吲哚啉类化合物及其制备方法 |
| SG11202112875UA (en) | 2019-06-20 | 2021-12-30 | Chemocentryx Inc | Compounds for treatment of pd-l1 diseases |
| BR112021025888A2 (pt) | 2019-07-10 | 2022-04-26 | Chemocentryx Inc | Indanos como inibidores de pd-l1 |
| AU2020368393B2 (en) | 2019-10-16 | 2026-01-08 | Chemocentryx, Inc. | Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases |
| CN114555080B (zh) | 2019-10-16 | 2025-10-10 | 凯莫森特里克斯股份有限公司 | 用于治疗pd-l1疾病的杂芳基联苯胺 |
| WO2021076890A1 (en) | 2019-10-16 | 2021-04-22 | Morphic Therapeutic, Inc. | INHIBITING HUMAN INTEGRIN α4β7 |
| WO2021262627A1 (en) | 2020-06-23 | 2021-12-30 | Chemocentryx, Inc. | Methods of treating cancer using heteroaryl-biphenyl amide derivatives |
-
2020
- 2020-10-15 CN CN202080073055.9A patent/CN114555080B/zh active Active
- 2020-10-15 EP EP20877362.2A patent/EP4045037B1/en active Active
- 2020-10-15 CA CA3152714A patent/CA3152714A1/en active Pending
- 2020-10-15 CR CR20220216A patent/CR20220216A/es unknown
- 2020-10-15 JP JP2022522679A patent/JP7686634B2/ja active Active
- 2020-10-15 KR KR1020227016266A patent/KR20220083775A/ko active Pending
- 2020-10-15 WO PCT/US2020/055669 patent/WO2021076688A1/en not_active Ceased
- 2020-10-15 BR BR112022006279A patent/BR112022006279A2/pt unknown
- 2020-10-15 AU AU2020368392A patent/AU2020368392B2/en active Active
- 2020-10-15 MX MX2022004450A patent/MX2022004450A/es unknown
- 2020-10-15 PE PE2022000617A patent/PE20221764A1/es unknown
- 2020-10-15 US US17/071,056 patent/US11866429B2/en active Active
- 2020-10-15 PH PH1/2022/550877A patent/PH12022550877A1/en unknown
- 2020-10-16 AR ARP200102872A patent/AR120246A1/es unknown
- 2020-10-16 TW TW109135945A patent/TWI873207B/zh active
-
2022
- 2022-03-27 IL IL291735A patent/IL291735A/en unknown
- 2022-04-13 CO CONC2022/0004698A patent/CO2022004698A2/es unknown
- 2022-04-14 CL CL2022000955A patent/CL2022000955A1/es unknown
- 2022-05-13 EC ECSENADI202238509A patent/ECSP22038509A/es unknown
-
2023
- 2023-11-29 US US18/522,995 patent/US12371433B2/en active Active
-
2025
- 2025-04-09 CL CL2025001073A patent/CL2025001073A1/es unknown
- 2025-07-23 US US19/277,892 patent/US20250346598A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220083775A (ko) | 2022-06-20 |
| BR112022006279A2 (pt) | 2022-06-28 |
| US12371433B2 (en) | 2025-07-29 |
| JP7686634B2 (ja) | 2025-06-02 |
| AU2020368392B2 (en) | 2026-01-08 |
| WO2021076688A1 (en) | 2021-04-22 |
| US11866429B2 (en) | 2024-01-09 |
| EP4045037C0 (en) | 2026-01-28 |
| ECSP22038509A (es) | 2022-06-30 |
| AU2020368392A1 (en) | 2022-04-21 |
| TWI873207B (zh) | 2025-02-21 |
| TW202128695A (zh) | 2021-08-01 |
| EP4045037A4 (en) | 2023-11-15 |
| PE20221764A1 (es) | 2022-11-11 |
| CN114555080B (zh) | 2025-10-10 |
| CA3152714A1 (en) | 2021-04-22 |
| EP4045037B1 (en) | 2026-01-28 |
| CO2022004698A2 (es) | 2022-04-29 |
| PH12022550877A1 (en) | 2023-03-27 |
| US20210130347A1 (en) | 2021-05-06 |
| EP4045037A1 (en) | 2022-08-24 |
| CL2022000955A1 (es) | 2023-01-13 |
| US20240132495A1 (en) | 2024-04-25 |
| JP2022551972A (ja) | 2022-12-14 |
| MX2022004450A (es) | 2022-05-03 |
| CL2025001073A1 (es) | 2025-08-01 |
| US20250346598A1 (en) | 2025-11-13 |
| CN114555080A (zh) | 2022-05-27 |
| IL291735A (en) | 2022-05-01 |
| CR20220216A (es) | 2023-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR120246A1 (es) | Aminas heteroaril-bifenilas para el tratamiento de las enfermedades por pd-l1 | |
| AR110139A1 (es) | COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR108396A1 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| AR110153A1 (es) | ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR117102A1 (es) | Inhibidores de arg1 y/o arg2 | |
| AR119088A1 (es) | Compuestos de 2,3,5-pirazolo[1,5-a]pirimidina trisustituida | |
| AR120684A1 (es) | INHIBIDORES DE HIF-2a | |
| AR100438A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
| AR117424A1 (es) | Inhibidores de los receptores erbb | |
| AR113964A1 (es) | Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa | |
| AR094174A1 (es) | Lactamas fusionadas de arilo y heteroarilo | |
| AR106595A1 (es) | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g | |
| AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| AR103252A1 (es) | Compuestos de quinazolina | |
| AR106865A1 (es) | Piridinas sustituidas y métodos de uso | |
| AR088423A1 (es) | Ligadores p1 ciclicos como inhibidores del factor xia | |
| AR087591A1 (es) | Derivados de ciclohexil azetidina como inhibidores de jak | |
| AR088748A1 (es) | Macrociclos como inhibidores del factor xia | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR087760A1 (es) | Heterociclilaminas como inhibidores de pi3k | |
| AR089865A1 (es) | Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio | |
| AR091981A1 (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk |